Dasatinib 100 Mg Oral Tablet

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Osteopenia, Osteoporosis

Conditions

Osteopenia, Osteoporosis, Age-related Bone Loss

Trial Timeline

Sep 6, 2023 → Apr 30, 2026

NCT ID

NCT06018467

About Dasatinib 100 Mg Oral Tablet

Dasatinib 100 Mg Oral Tablet is a phase 2 stage product being developed by Novo Nordisk for Osteopenia, Osteoporosis. The current trial status is active. This product is registered under clinical trial identifier NCT06018467. Target conditions include Osteopenia, Osteoporosis, Age-related Bone Loss.

What happened to similar drugs?

5 of 10 similar drugs in Osteopenia, Osteoporosis were approved

Approved (5) Terminated (0) Active (5)

✅Teriparatide + Zoledronic AcidEli LillyApproved

✅alendronate sodiumMerckApproved

✅zoledronic acid vs pamidronateNovartisApproved

✅Placebo + ibandronate [Bonviva/Boniva]RocheApproved

✅tibolone + raloxifenOrganonApproved

🔄zoledronic acidNovartisPhase 3

🔄Zoledronic Acid + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06018467	Phase 2	Active	Sep 6, 2023	Apr 30, 2026	Osteopenia, Osteoporosis

Competing Products

18 competing products in Osteopenia, Osteoporosis

See all competitors

Product	Company	Stage	Hype Score
Teriparatide + Zoledronic Acid	Eli Lilly	Approved	43
alendronate sodium	Merck	Approved	43
zoledronic acid	Novartis	Phase 3	40
zoledronic acid vs pamidronate	Novartis	Approved	43
Zoledronic Acid + Placebo	Novartis	Phase 3	40
BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804	Novartis	Phase 2	35
Placebo + ibandronate [Bonviva/Boniva]	Roche	Approved	43
ibandronate [Bonviva/Boniva] + Placebo	Roche	Phase 3	40
Romosozumab + Placebo	Amgen	Phase 1	29
Placebo + AMG 167	Amgen	Phase 1	29
AMG 167 + Placebo	Amgen	Phase 1	29
Romosozumab + Placebo	Amgen	Phase 1	29
Denosumab	Amgen	Phase 3	40
Romosozumab + Placebo	Amgen	Phase 1	29
RN564	Pfizer	Phase 1	29
risedronate + alendronate	Sanofi	Phase 1	29
Menostar (Estradiol, BAY86-5435) + Raloxifene	Bayer	Phase 3	37
tibolone + raloxifen	Organon	Approved	37